Establishing Research With Horizon Therapeutics' Robert Stoffel, Ph.D.

We love to hear from our listeners. Send us a message. While Horizon Therapeutics has made plenty of waves in the biotech news cycle of late. While perhaps not as flashy as a perilous multibillion dollar acquisition deal or potential blockbuster readout, its formal establishment of a research team – comparatively pragmatic as that may be – could have long-term consequences that are just impactful. On this week's episode of the Business of Biotech, we dig into why the company chose to establish a research function, learn why it chose Dr. Robert Stoffel, Ph.D. to run it, and get a step-by-step explainer on how Stoffel went about establishing the department, setting its goals and strategy, staffing it, and integrating it across teams at the fast-rising biopharmaceutical company. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.  Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: [email protected] Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/